National Health Research Institutes (NHRI) and Taivex Therapeutics Corp (Taivex) have signed the technology transfer agreement in September, 2021. Taivex has granted the exclusive rights of the small molecule Mertansine conjugate, T-1501, with global patents. About DBPR186Phospholipid phosphatidylserine (PS), abundant on the external surfaces of cancer cells, is an established target molecule for cancer therapy. T-1501 is a developmental drug candidate for …

Following IND approval by the US FDA in Mid-June, 2021, Taivex submitted the Phase I clinical trial application to the Taiwan FDA later on June 28 and received approval on August 20. The anticipated initiation of the Phase I trial remains by end of 2021. T-1301 Phase I trial is a multi-centered study in Taiwan. The oral solid dosage form …

T-1201 which IND application has been approved by US FDA and TFDA and the Phase I clinical trial has been initiated in June, 2021. T-1201 is a small molecular drug conjugate (SMDC), exhibiting potential of multiple anti-cancer indications. The Phase I trial is to evaluate safety and tolerability of T-1201, the recommended Phase 2 dose (RP2D), and the pharmacokinetics in …

Taivex received US FDA Investigational New Drug Application (IND) Approval for T-1301 on June 17, 2021, to initiate phase I clinical trial for the treatment of advanced solid tumors. T-1301 is a small molecular oral anti-cancer drug licensed from National Health Research Institutes in 2019. After completion of pre-clinical safety evaluation, as well as chemistry, manufacture and control of drug …